



PELLETS AND DC GRANULES PLANT AT VIZAG


- State-of-the-art facility with 20,000 SFT built-up area
- Annual Capacity 1200 MT
- Four production modules
- Product range includes Immediate Release, Sustained Release, Extended Release, Modified Release Pellets, Blended Pellets, Pre-mixes, MUPS, and DC Granules

PRODUCTS OFFERED

PELLETS DR / IR	Product Name	Strength (w/w)	Specification
	Esomeprazole Mg EC Pellets	8.5%, 22.5%	IHS/USP
	Itraconazole IR Pellets	22%, 40%, 44%	IP/BP/USP
	Lansoprazole EC Pellets	8.5%	IHS/USP
	Omeprazole EC Pellets	7.5%, 8.5%, 15%, 22.5%	IHS/USP
	Pantoprazole Na EC Pellets	15%, 22.5%	IHS/IP

PRODUCTS VALIDATED & UNDER STABILITY

PELLETS	IR	Product Name	Strength (w/w)	Specification
		Atorvastatin Ca IR Pellets	7%, 10%	USP
		Clopidogrel Bisulphate IR Pellets	55%	USP
		Domperidone IR Pellets	10%, 20%	IP/IHS
		Dutasteride IR Pellets	0.32%	USP
		Itraconazole IR Pellets	22%, 40%, 44%	IP/BP/USP/IHS
	SR/MR	Telmisartan IR Pellets	20%	USP
		Domperidone SR Pellets	22%	IP/IHS
		Mebeverine HCl SR Pellets	52.36%	IP/IHS
	DR	Tamsulosin HCl SR/MR Pellets	0.16%, 0.2%	USP
		Esomeprazole Mg EC Pellets	8.5%, 22.5%	USP
		Lansoprazole EC Pellets	8.5%	USP
		Omeprazole EC Pellets	7.5%, 8.5%, 10%, 15%, 22.5%, 30%	USP
		Pantoprazole Na EC Pellets	15%, 22.5%, 30%	IP
	Rabeprazole Na EC Pellets	15%	IP/IHS	
MUPS Micro Pellets	Esomeprazole Mg DR Micro Pellets	8.5%, 22.5%	USP	
	Itraconazole IR Micro Pellets	22%	BP	
	Lansoprazole DR Micro Pellets	8.5%	USP	
	Omeprazole DR Micro Pellets	8.5%	USP	
	Pantoprazole Na DR Micro Pellets	15%	IP	



PRODUCTS VALIDATED & UNDER STABILITY			
	Product Name	Strength (w/w)	Specification
BLENDED Pellets	Pantoprazole Na EC + Domperidone SR	40 mg + 30 mg	IP
	Rabeprazole Na EC + Domperidone SR	20 mg + 30 mg	IP
	Omeprazole EC + Domperidone IR	20 mg + 10 mg	IP
	Atorvastatin IR + Clopidogrel IR	10 mg + 75 mg	IHS
	Tamsulosin HCl SR + Dutasteride IR	0.4 mg + 0.5 mg	IP
	Esomeprazole Mg EC + Domperidone SR	40 mg + 30 mg	IHS
DC GRANULES	Guaifenesin	95%	USP
	Guaifenesin ER	94.9%	USP
	Metformin HCl	94.16%, 95.24%	USP
	Paracetamol/Acetaminophen	79.37%, 83.33%, 90%	USP
	Paracetamol/ Acetaminophen ER	88%	USP
PELLETS EC/DR/IR	Esomeprazole Mg EC/DR Pellets	8.5%, 15%, 22.5%, 23.5%	USP/IHS
	Itraconazole IR Pellets	20%, 22%, 40%, 44%	USP/BP/IHS
	Lansoprazole EC/DR Pellets	8.5%	USP/IHS
	Omeprazole EC /DR Pellets	7.5%, 8.5%, 15%, 22.5%	USP/IHS
	Pantoprazole Na EC/DR Pellets	15%, 22.5%	IP/IHS
PRODUCTS UNDER DEVELOPMENT			
	Product Name	Strength (w/w)	Specification
PELLETS / MUPS DDR/EC/DR/IR/SR	Dexlansoprazole EC/DR Pellets	17%, 22.5%	IHS
	Dexlansoprazole DDR Pellets	20%, 22.5%	IHS
	Duloxetine HCl EC/DR Pellets	11%	IHS
	Duloxetine HCl SR Pellets	11%, 17%, 20%	USP
	Orlistat IR Pellets	40%, 50%	USP
	Tamsulosin HCl SR MUPS	0.16%	USP
	Venlafaxine HCl SR Pellets	33%	USP
DC GRANULES IR/MR/ER	Guaifenesin IR	55%	IHS
	Paracetamol MR	84%	USP
	Metformin ER	58%	USP

Disclaimer : "Smilax Laboratories Limited respects Patent laws and conventions of Pharmaceuticals as applicable in different countries. Products covered by valid patents are not offered or supplied for commercial use in those countries. It is Buyer's / Customer's responsibility to ensure that such commercial activity does not infringe any applicable patent rights".